Panelists discuss how diagnosis and staging of anal cancer involves digital rectal examination, high-resolution anoscopy with biopsy, p16 testing, and pelvic MRI for accurate staging, while ...

A study led by clinician-scientists and researchers at the National Cancer Centre Singapore (NCCS) has found that the tumor immune microenvironment (TIME) plays a critical role in the progression of ...

On Jan. 24, the FDA issued a warning about the enzyme deficiency in which it urged health care providers to “inform patients prior to treatment” about the risks of taking 5-FU and capecitabine. On ...

You have tucatinib, trastuzumab and capecitabine as cycles of treatment. This means you have the drugs and then a rest to allow your body to recover. Each cycle of treatment lasts 21 days (3 weeks).

Capecitabine (Xeloda®), an oral medication, has been demonstrated to have equal effect as its intravenous counterpart 5-FU in treating colon, [25,26] as well as gastroesophageal, cancers.

Landmark study uncovers role of tumour microenvironment in nasopharyngeal carcinoma progression which supports personalised treatment Molecular ...

Around 300,000 people are treated with 5-FU or capecitabine in the United States each year, but its toxicity could well have prevented FDA approval were it up for approval today. Short of withdrawing ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

They randomly assigned 748 patients (median age, 59 years; range, 24-75; 69.7% men) to receive capecitabine and oxaliplatin plus either 12 mg daily anlotinib (days 1-14) or 7.5 mg/kg IV ...

In part 1 of LEAP-015 (Lead-in Phase), an initial cohort received induction with lenvatinib 8 mg orally once daily plus pembrolizumab 400 mg intravenously once every 6 weeks (×2) and investigator’s ...